|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ghislain I, Zikos E, Coens C, Quinten C,
Balta V, Tryfonidis K, Piccart M, Zardavas D, Nagele E,
Bjelic-Radisic V, et al: Health-related quality of life in locally
advanced and metastatic breast cancer: Methodological and clinical
issues in randomised controlled trials. Lancet Oncol. 17:e294–e304.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goitea VE and Hallak ME: Calreticulin and
arginylated calreticulin have different susceptibilities to
proteasomal degradation. J Biol Chem. 290:16403–16414. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Holmström MO, Ocias LF, Kallenbach K, Kjær
L, Kristensen TK, Pallisgaard N, Petersen BL, Skov V, de Stricker
K, Larsen TS, et al: New disease markers within the chronic
myeloproliferative neoplasms. Ugeskr Laeger. 1772015.(In
Danish).
|
|
5
|
Wang WA, Groenendyk J and Michalak M:
Calreticulin signaling in health and disease. Int J Biochem Cell
Biol. 44:842–846. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zamanian M, Veerakumarasivam A, Abdullah S
and Rosli R: Calreticulin and cancer. Pathol Oncol Res. 19:149–154.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lwin ZM, Guo C, Salim A, Yip GW, Chew FT,
Nan J, Thike AA, Tan PH and Bay BH: Clinicopathological
significance of calreticulin in breast invasive ductal carcinoma.
Mod Pathol. 23:1559–1566. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hayashida Y, Urata Y, Muroi E, Kono T,
Miyata Y, Nomata K, Kanetake H, Kondo T and Ihara Y: Calreticulin
represses E-cadherin gene expression in Madin-Darby canine kidney
cells via Slug. J Biol Chem. 281:32469–32484. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu SH, Lee WJ, Lai DW, Wu SM, Liu CY,
Tien HR, Chiu CS, Peng YC, Jan YJ, Chao TH, et al: Honokiol confers
immunogenicity by dictating calreticulin exposure, activating ER
stress and inhibiting epithelial-to-mesenchymal transition. Mol
Oncol. 9:834–849. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wieser R: The oncogene and developmental
regulator EVI1: Expression, biochemical properties, and biological
functions. Gene. 396:346–357. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Daghistani M, Marin D, Khorashad JS, Wang
L, May PC, Paliompeis C, Milojkovic D, De Melo VA, Gerrard G,
Goldman JM, et al: EVI-1 oncogene expression predicts survival in
chronic-phase CML patients resistant to imatinib treated with
second-generation tyrosine kinase inhibitors. Blood. 116:6014–6017.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gröschel S, Lugthart S, Schlenk RF, Valk
PJ, Eiwen K, Goudswaard C, van Putten WJ, Kayser S, Verdonck LF,
Lübbert M, et al: High EVI1 expression predicts outcome in younger
adult patients with acute myeloid leukemia and is associated with
distinct cytogenetic abnormalities. J Clin Oncol. 28:2101–2107.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vázquez I, Maicas M, Cervera J, Agirre X,
Marin-Béjar O, Marcotegui N, Vicente C, Lahortiga I, Gomez-Benito
M, Carranza C, et al: Down-regulation of EVI1 is associated with
epigenetic alterations and good prognosis in patients with acute
myeloid leukemia. Haematologica. 96:1448–1456. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Patel JB, Appaiah HN, Burnett RM,
Bhat-Nakshatri P, Wang G, Mehta R, Badve S, Thomson MJ, Hammond S,
Steeg P, et al: Control of EVI-1 oncogene expression in metastatic
breast cancer cells through microRNA miR-22. Oncogene.
30:1290–1301. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Koos B, Bender S, Witt H, Mertsch S,
Felsberg J, Beschorner R, Korshunov A, Riesmeier B, Pfister S,
Paulus W and Hasselblatt M: The transcription factor evi-1 is
overexpressed, promotes proliferation, and is prognostically
unfavorable in infratentorial ependymomas. Clin Cancer Res.
17:3631–3637. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Deng X, Cao Y, Liu Y, Li F, Sambandam K,
Rajaraman S, Perkins AS, Fields AP, Hellmich MR, Townsend CM Jr, et
al: Overexpression of Evi-1 oncoprotein represses TGF-β signaling
in colorectal cancer. Mol Carcinog. 52:255–264. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Venkov CD, Link AJ, Jennings JL, Plieth D,
Inoue T, Nagai K, Xu C, Dimitrova YN, Rauscher FJ and Neilson EG: A
proximal activator of transcription in epithelial-mesenchymal
transition. J Clin Invest. 117:482–491. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Venkov C, Plieth D, Ni T, Karmaker A, Bian
A, George AL Jr and Neilson EG: Transcriptional networks in
epithelial-mesenchymal transition. PLoS One. 6:e253542011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nayak KB, Sajitha IS, Kumar TRS and
Chakraborty S: Ecotropic viral integration site 1 promotes
metastasis independent of epithelial mesenchymal transition in
colon cancer cells. Cell Death Dis. 9:182018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Goyama S and Kurokawa M: Evi-1 as a
critical regulator of leukemic cells. Int J Hematol. 91:753–757.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lugthart S, van Drunen E, van Norden Y,
van Hoven A, Erpelinck CA, Valk PJ, Beverloo HB, Löwenberg B and
Delwel R: High EVI1 levels predict adverse outcome in acute myeloid
leukemia: Prevalence of EVI1 overexpression and chromosome 3q26
abnormalities underestimated. Blood. 111:4329–4337. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Barjesteh van Waalwijk van
Doorn-Khosrovani S, Erpelinck C, van Putten WL, Valk PJ, van der
Poel-van de Luytgaarde S, Hack R, Slater R, Smit EM, et al: High
EVI1 expression predicts poor survival in acute myeloid leukemia: A
study of 319 de novo AML patients. Blood. 101:837–845. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dhanasekaran DN and Reddy EP: JNK
signaling in apoptosis. Oncogene. 27:6245–6251. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Aoki H, Kang PM, Hampe J, Yoshimura K,
Noma T, Matsuzaki M and Izumo S: Direct activation of mitochondrial
apoptosis machinery by c-Jun N-terminal kinase in adult cardiac
myocytes. J Biol Chem. 277:10244–10250. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang CB, Pei WJ, Zhao J, Cheng YY, Zheng
XH and Rong JH: Bornyl caffeate induces apoptosis in human breast
cancer MCF-7 cells via the ROS- and JNK-mediated pathways. Acta
Pharmacol Sin. 35:113–123. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kurokawa M, Mitani K, Yamagata T,
Takahashi T, Izutsu K, Ogawa S, Moriguchi T, Nishida E, Yazaki Y
and Hirai H: The evi-1 oncoprotein inhibits c-Jun N-terminal kinase
and prevents stress-induced cell death. Embo J. 19:2958–2968. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Garrison SP, Phillips DC, Jeffers JR,
Chipuk JE, Parsons MJ, Rehg JE, Opferman JT, Green DR and Zambetti
GP: Genetically defining the mechanism of Puma- and Bim-induced
apoptosis. Cell Death Differ. 19:642–649. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rossé T, Olivier R, Monney L, Rager M,
Conus S, Fellay I, Jansen B and Borner C: Bcl-2 prolongs cell
survival after Bax-induced release of cytochrome c. Nature.
391:496–499. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Brooks C and Dong Z: Regulation of
mitochondrial morphological dynamics during apoptosis by Bcl-2
family proteins: A key in Bak? Cell Cycle. 6:3043–3047. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang J, Liu X, Bhalla K, Kim CN, Ibrado
AM, Cai J, Peng TI, Jones DP and Wang X: Prevention of apoptosis by
Bcl-2: Release of cytochrome c from mitochondria blocked. Science.
275:1129–1132. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cheng EH, Kirsch DG, Clem RJ, Ravi R,
Kastan MB, Bedi A, Ueno K and Hardwick JM: Conversion of Bcl-2 to a
Bax-like death effector by caspases. Science. 278:1966–1968. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang Y, Goodyer C and LeBlanc A:
Selective and protracted apoptosis in human primary neurons
microinjected with active caspase-3, −6, −7, and −8. J Neurosci.
20:8384–8389. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cryns V and Yuan J: Proteases to die for.
Genes Dev. 12:1551–1570. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang Y, Duan W, Liang Z, Yi W, Yan J, Wang
N, Li Y, Chen W, Yu S, Jin Z and Yi D: Curcumin attenuates
endothelial cell oxidative stress injury through Notch signaling
inhibition. Cell Signal. 25:615–629. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lončarević-Vasiljković N, Milanović D,
Pešić V, Tešić V, Brkić M, Lazić D, Avramović V and Kanazir S:
Dietary restriction suppresses apoptotic cell death, promotes Bcl-2
and Bcl-xl mRNA expression and increases the Bcl-2/Bax protein
ratio in the rat cortex after cortical injury. Neurochem Int.
96:69–76. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sazawal S, Singh N, Mahapatra M and Saxena
R: Calreticulin mutation profile in Indian patients with primary
myelofibrosis. Hematology. 20:567–570. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chiang WF, Hwang TZ, Hour TC, Wang LH,
Chiu CC, Chen HR, Wu YJ, Wang CC, Wang LF, Chien CY, et al:
Calreticulin, an endoplasmic reticulum-resident protein, is highly
expressed and essential for cell proliferation and migration in
oral squamous cell carcinoma. Oral Oncol. 49:534–541. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Raghavan M, Wijeyesakere SJ, Peters LR and
Del Cid N: Calreticulin in the immune system: Ins and outs. Trends
Immunol. 34:13–21. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li X, Wang X, Tan Z, Chen S and Guan F:
Role of glycans in cancer cells undergoing epithelial-mesenchymal
transition. Front Oncol. 6:332016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Morra L and Moch H: Periostin expression
and epithelial-mesenchymal transition in cancer: A review and an
update. Virchows Arch. 459:465–475. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xiong H, Hong J, Du W, Lin YW, Ren LL,
Wang YC, Su WY, Wang JL, Cui Y, Wang ZH and Fang JY: Roles of STAT3
and ZEB1 proteins in E-cadherin down-regulation and human
colorectal cancer epithelial-mesenchymal transition. J Biol Chem.
287:5819–5832. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jiang Y, Dey S and Matsunami H:
Calreticulin: Roles in cell-surface protein expression. Membranes
(Basel). 4:630–641. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lu Z, Wang J, Zheng T, Liang Y, Yin D,
Song R, Pei T, Pan S, Jiang H and Liu L: FTY720 inhibits
proliferation and epithelial-mesenchymal transition in
cholangiocarcinoma by inactivating STAT3 signaling. BMC Cancer.
14:7832014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ihara Y, Inai Y and Ikezaki M: Alteration
of integrin-dependent adhesion and signaling in EMT-like MDCK cells
established through overexpression of calreticulin. J Cell Biochem.
112:2518–2528. 2011. View Article : Google Scholar : PubMed/NCBI
|
